Sermonix Pharmaceuticals’ Lasofoxifene Demonstrates Anti-Estrogen Therapy Increases Immunotherapy Efficacy by Promoting Antitumor Activity of Eosinophils
01. Oktober 2024 09:00 ET
|
Sermonix Pharmaceuticals Inc.
The findings were published Sept. 27 in the peer-reviewed journal Science AdvancesLasofoxifene was more effective than fulvestrant in inhibiting estrogen activity in mice models COLUMBUS, Ohio,...